Viatris slides as FDA scrutiny on India plant clouds outlook
by
Contributor since / Followers
Contributor since / Followers
2 weeks ago
mohd izzuan
Shares of Viatris (NASDAQ:VTRS) slipped ~12% in the premarket on Thursday after the generic drugmaker, with its Q4 2024 results, set its full-year outlook below expectations amid a negative impact from remediation work at an India plant.
The company said